A large proportion of colorectal cancers (CRCs) display mutational inactivation of the TGF-b pathway, yet, paradoxically, they are characterized by elevated TGF-b production. Here, we unveil a prometastatic program induced by TGF-b in the microenvironment that associates with a high risk of CRC relapse upon treatment. The activity of TGF-b on stromal cells increases the efficiency of organ colonization by CRC cells, whereas mice treated with a pharmacological inhibitor of TGFBR1 are resilient to metastasis formation. Secretion of IL11 by TGF-b-stimulated cancer-associated fibroblasts (CAFs) triggers GP130/STAT3 signaling in tumor cells. This crosstalk confers a survival advantage to metastatic cells. The dependency on the TGF-b stromal program for metastasis initiation could be exploited to improve the diagnosis and treatment of CRC.
INTRODUCTION
Most colorectal cancers (CRCs) originate from the intestinal epithelium as premalignant lesions called adenomas. Over time, a small fraction of adenomas are transformed to CRCs because of the accumulation of genetic alterations in a small set of driver genes, including KRAS, TP53, SMAD4, or PIK3CA (Markowitz and Bertagnolli, 2009) . Alterations in these and other cancer-causing genes have been associated with the different stages of the progression of the tumor (i.e., transition from normal intestinal mucosa to adenoma and further progression to CRC). In contrast, metastases that are either present at the time of diagnosis or develop as distant relapses after therapy are not strongly associated with alterations in any of these key Significance About 40%-50% of all patients with colorectal cancer will present with metastasis either at the time of diagnosis or as recurrent disease upon intended curative therapy. In the absence of genetic alterations that explicate these processes, it remains a major challenge to predict which patients will develop metastatic disease or to design targeted therapies. Here, we show that metastasis depends on a gene program expressed by the tumor microenvironment upon TGF-b stimulation. Low stromal TGF-b signaling is a robust predictor of disease-free survival after therapy, which improves on the current AJCC staging system. Furthermore, colonization of foreign organs requires TGF-b signaling in stromal cells and therefore may be a target for therapeutic intervention at early time points of the metastatic process.
genes (Walther et al., 2009 ). In addition, global genome sequencing of metastatic lesions and primary CRCs revealed hardly any metastasis-specific mutation (Jones et al., 2008) . This drawback has hampered the development of metastasis-specific therapies, as well as the identification of patients with CRC at risk of suffering metastatic disease.
Mutational inactivation of the TGF-b signaling pathway is key during CRC progression. Alterations in TGF-b pathway components are first detected in advanced adenomas and affect 40%-50% of all CRCs Markowitz and Bertagnolli, 2009) . In mouse models, mutations in the tumor suppressor Apc combined with inactivation of TGF-b signaling components in epithelial intestinal cells trigger the development of invasive adenocarcinomas (Muñ oz et al., 2006; Takaku et al., 1998) . Restoration of a functional TGF-b pathway in human CRC cells abrogates proliferation and tumorigenicity , implying that TGF-b signaling exerts tumor-suppressive effects. Hence, it has been proposed that TGF-b imposes a selective pressure during CRC progression, which tumors avert by genetic inactivation of the TGF-b receptors (TGFBR1 and TGFBR2) or of the SMAD intracellular mediators (SMAD4, SMAD2, and SMAD3) (Grady and Markowitz, 2002; Markowitz et al., 1995; Markowitz and Bertagnolli, 2009 ).
In addition to its tumor suppressor role in epithelial cells, TGF-b signaling also acts as a negative regulator of tumor formation by conditioning mucosa-resident stromal cells. Mice with a deletion of Smad4 in T cells develop gastrointestinal tumors (Hahn et al., 2011; Kim et al., 2006) . Similarly, transgenic expression of a dominant negative TGFBR2 in T cells accelerates azoxymethane-induced colon carcinogenesis (Becker et al., 2004) . In both cases, T cells lacking TGF-b signals exacerbate the production of proinflammatory cytokines that spark off the transformation of the colonic epithelium (Becker et al., 2004; Kim et al., 2006) .
Although the above genetic and mutational data support a tumor suppressor role for TGF-b signaling in intestinal carcinogenesis, high levels of TGFB1 in the serum of patients with CRC are associated with poor outcome in the clinical setting (Tsushima et al., 2001) . The relevance of TGF-b signaling for disease progression has been widely recognized in tumors where cancer cells retain a functional TGF-b pathway, such as breast or prostate cancer (Massagué , 2008) . In these tumor cells, TGF-b induces a variety of prometastatic programs that range from induction of epithelial-to-mesenchymal transition to expression of genes that allow colonization of foreign organs (Massagué , 2008) . It is less clear, however, what CRC cells can gain from high TGF-b levels once the pathway is fully inactivated by mutations and how this phenomenon links to an adverse outcome. To address this apparent paradox, we investigated whether TGF-b may activate the tumor microenvironment to assist CRC cells in the metastatic process.
RESULTS

TGF-b Levels in CRC Are a Robust Predictor of Disease Relapse
We first investigated whether differences in TGF-b levels in primary tumors were associated with clinical disease progression in CRC. To this end, we interrogated a representative pooled cohort of 345 cases treated at three different hospitals for which transcriptomic profiles and clinical follow-up were publicly available. In this metacohort, overall TGF-b levels were low in patients with American Joint Cancer Committee (AJCC) stage I cancer, compared to cancer at more advanced stages ( Figure 1A ; see Tables S1 and S2 available online) . The AJCC staging system has limited power to predict disease relapse, because 10%-20% of patients with stage II CRC and 30%-50% of patients with stage III CRC will develop recurrent cancer after therapeutic intervention. We found that, for every increase in overall TGF-b (TGFB) expression, the risk of cancer recurrence augmented by 83% ( Figure 1B) . As a consequence, we observed large differences in the frequency of disease relapse after therapy in patients bearing tumors with high, medium, or low TGFB ( Figure 1C ) or individual TGF-b isoform levels (Figures S1A and S1B). During 10 years of follow-up, only patients with medium or high TGFB expression in the primary tumor (53 of 220 patients) suffered cancer recurrence. Remarkably, all patients bearing TGFB-low tumors remained disease-free (Figure 1C, blue group) . High TGFB levels were robustly associated with relapse in patients with stage II and III cancer, whereas low TGFB characterized a small set of patients with no observed recurrences in both stages ( Figure 1D ; 17% and 11% of patients with cancer at these stages, respectively). The rare relapses occurring in stage I CRCs (2 of 35 patients in this group) also expressed high TGFB levels ( Figure 1D ), although this comparison did not reach statistical significance, probably because of the low incidence of recurrences in this stage. Cox proportional hazards multivariate analysis demonstrated that TGFB expression is an independent predictor of cancer recurrence that outperforms AJCC staging system in the identification of patients with CRC who remained disease free upon therapy ( Figure 1E ). The predictive power of TGFB levels also compared favorably to that of other genes that have been repeatedly associated with disease relapse in CRC (Table S3) .
TGF-b Response Signatures in Tumor-Associated Stromal Cells Predict Disease Relapse in CRC
An increase in TGF-b isoform levels was evident at the adenoma-CRC transition, as shown by expression profiling of a small cohort of colon tumors ( Figure S1C ). Nuclear p-SMAD3, a marker for TGF-b signaling, stained predominantly the stromal compartment in most CRCs ( Figure S1D ). In the majority of samples, epithelial CRC cells were markedly less stained compared to adjacent stromal cells or to the epithelial compartment of adenomas ( Figures S1D-S1F) . We characterized the stromal cell types stained by p-SMAD3 in CRCs but could not discriminate any obvious cell-type specificity. Rather, p-SMAD3 indiscriminately labeled all major types of stromal cells in CRCs, including T cells, macrophages, endothelial cells, and fibroblasts ( Figures S2A-S2H ). We thus quantified the association of TGF-b-activated stromal cell populations with disease progression. To this end, we used as surrogates the gene expression programs induced by the addition of TGF-b (TGF-b response signatures or TBRS) in cultures of normal-tissue-derived T cells (T-), macrophages (Ma-), endothelial cells (End-), or fibroblasts (F-). To avoid biases, we used the full set of genes upregulated by TGF-b signaling in these cell cultures (>2 fold, p < 0.05) without additional filtering or refinement (Table S4) . By Gene Figure S1 . (Subramanian et al., 2005) , we determined that all stromal TBRSs were highly enriched in CRCs compared to adenomas (Figure 2A) . Importantly, the expression levels of TGFB, F-TBRS, T-TBRS, and Ma-TBRS showed robust direct correlations in the cohort of patients with CRC ( Figure 2B ), implying that they are, to a large extent, concurrently expressed in CRC. Significantly, these three signatures were excellent predictors of disease relapse in patients with stage I, II, and III CRC and segregated a low-expression patient group with virtually no risk of developing recurrent cancer after therapy ( Figures 2C and 2D , blue group). This result paralleled that obtained with TGFB levels (Figure 1 ). In patients with stage IV CRC who underwent potential curative therapy, high TGFB and stromal TBRS expression levels also correlated with higher risk of relapse ( Figures S2I-S2L ). However, a large proportion of these patients with stage IV disease eventually experienced relapse, likely because of the lack of effective therapies to eliminate an overt metastatic disease. Consistent with their ability to predict disease progression, the stromal TBRS included several well-known prometastatic genes, such as ANGPTL4 (Padua et al., 2008) , PTHLH (Yin et al., 1999) , HBEGF (Bos et al., 2009) , CTGF (Kang et al., 2003) , TNC (Oskarsson et al., 2011) , or JAG1 (Sethi et al., 2011; Sonoshita et al., 2011) , all of which encode for secreted or membranebound factors (Table S4) .
To further analyze the cell-type-specific expression of each stromal TBRS in vivo, we purified by FACS various cell populations from fresh CRC samples and assessed their gene expression profiles (Figures 2E and 2F) . Relative levels of cell-type-specific marker genes confirmed the purification of epithelial tumor cells (EPCAM Figure 2G ). Remarkably, these trends became very significant for those genes within the T-TBRS, Ma-TBRS, or End-TBRS that associated positively with cancer relapse (HR > 1, p < 0.05; Figure 2H ). Although the in vitro derived End-TBRS did not predict disease progression ( Figures 2C and 2D ), we observed elevated expression of recurrence-associated TGF-b target genes in endothelial cells directly purified from tumors ( Figure 2H ). This observation may suggest that the response of in vitro cultured endothelial cells to TGF-b signaling deviates significantly from that occurring in the tumor microenvironment. Altogether, these data highlight that the response of stromal cells to TGF-b is an accurate predictor of disease relapse in patients with CRC. Although high TGFB levels activate gene programs in a wide range of tumor-associated stromal cell types, our in vivo data indicate that CAFs and, to a lesser extent, endothelial cells are the main contributors to the association of stromal TGF-b-driven programs with poor outcome after therapy.
TGF-b Signaling in the Stroma Promotes Tumor Initiation
The above data suggest the possibility that elevated TGFB levels in CRC influence disease progression by acting on stromal cells. S3D ). Yet, this genetic alteration did not impede the nuclear accumulation of p-SMADs ( Figure 3B ), as previously reported for other SMAD4 mutant cell lines (Alarcó n et al., 2009; Liu et al., 1997) . Therefore, the xenografts derived from these cells combine a TGF-b response in tumor stromal cells with lack of TGF-b signaling in cancer cells, the scenario characteristic of advanced CRC. We inoculated CRC cells subcutaneously into nude mice in quantities that generated suboptimal engraftment in control conditions (see Experimental Procedures). Elevated levels of TGF-b dramatically increased the frequency of tumor formation and reduced the latency period in all cell lines ( Figure 3D ). Yet, after tumor initiation, the TGF-b-activated microenvironment had no effect on xenograft growth rates ( Figure 3E ; data not shown). We further tested this early requirement by controlling the timing of TGF-b production in HT29-M6 CRC cells via a doxycycline-inducible promoter ( Figures 3F and 3G) . Secretion of TGF-b during the first 24 hr following inoculation of tumor cells was sufficient to enhance tumor initiation ( Figure 3G ). Given the well-established role of TGF-b in the polarization and suppression of the immune system in tumors (Flavell et al., 2010) , we tested whether the enhancement of tumor initiation by TGF-b signaling could be explained by modulation of the immune system. To this end, we injected CRC cells in severely immunocompromised mice of the NOD/SCID interleukin-2 receptor gamma chain null strain (NSG) (Shultz et al., 2007) . In these NSG mice, high TGF-b levels were also capable of enhancing tumor initiation, although fewer cancer cells were required to form tumors in this strain ( Figure S3E ).
Stromal TGF-b Signaling Is Required for Efficient Metastasis Initiation
CRCs at stages I, II, and III displaying low stromal TGF-b signaling fail to form recurrences, which, in most patients with CRC, occur in the form of metastasis. To study whether stromal TGF-b signaling may influence metastasis formation, we inoculated KM12L4a
Con and KM12L4a TGF-b cells in the cecum of nude mice. Both cell lines gave rise to aggressive colorectal tumors, which killed mice by obstruction of the intestinal lumen. At death, KM12L4a
Con and KM12L4a TGF-b had generated colon tumors of equivalent size (data not shown) with no significant differences in their degree of invasion, spread to local lymph nodes, or major histological features ( Figure 4A ; Figures S4A  and S4B ). Yet, two thirds of mice bearing KM12L4a Con colon tumors remained metastasis free, whereas 10 of 11 mice inoculated with KM12L4a
TGF-b cells developed lung and/or liver metastasis (p < 0.01, Figure 4B ). These data imply that stromal TGF-b signaling promotes metastasis formation. We further explored this phenomenon by using intrasplenic inoculation of CRC cells (Morikawa et al., 1988) . Secretion of TGF-b by KM12L4a cells increased the liver metastases burden in mice ( Figure 4C ). We also observed a large increase in the number of liver metastases generated by HT29-M6 secreting TGF-b ( Figure 4D ). In addition, a significant fraction of mice inoculated with KM12L4a TGF-b or HT29-M6 TGF-b developed lung metastases, implying that TGF-b signaling also facilitated secondary organ colonization ( Figure 4E ). The kinetics of liver metastasis revealed that control or TGF-b secreting cells expanded with similar rates once tumor cells had taken root and resumed growth (from day 7 in Figure 4F ). However, during the first few days following inoculation, most KM12L4a Con cells that reached the liver were progressively lost, and by 7 days, tumor cells were barely detectable ( Figure 4F ). A virtually complete loss of control metastatic cells was noticed during the first 24 hr upon inoculation of lower tumor cell numbers ( Figure S4C ). Secretion of TGF-b significantly increased the amounts of KM12L4a cells detected at these early time points ( Figure 4F ; Figure S4C ). To further test this early requirement, we used CRC cells that expressed TGF-b from a doxycycline-inducible promoter. A short pulse of TGF-b (24 hr) at the moment of intrasplenic inoculation was sufficient to increase metastasis burden by facilitating metastasis initiation without affecting subsequent tumor growth (Figures 4G and 4H ; Figure S4D ; p < 0.05). Thus, high levels of TGF-b specifically act to enhance the colonization capability of CRC cells at the initial phase of metastasis. Because KM12L4a and HT29-M6 cells harbor an inactivated TGF-b pathway, enhanced metastasis initiation by TGF-b secretion must be the consequence of changes in the tumor microenvironment. Indeed, metastasis derived by both TGF-b secreting cell lines displayed enhanced desmoplastic reaction ( Figures S4E-S4L ) with abundant p-SMAD2 accumulation in stromal cells (Figures  4I and 4J ; Figures S4M and S4N ) and elevated expression of stromal TBRS genes ( Figure 4K ; data not shown).
Pharmacological Inhibition of Stromal TGF-b Signaling Blocks Metastasis Initiation
We have recently described the purification of Colon Cancer Stem Cells (CoCSCs) from CRC biopsies via surface expression of the receptor tyrosine kinase EPHB2 (Merlos-Suá rez et al., 2011). We isolated EPHB2-high CoCSCs from the primary tumor of a patient with stage IV CRC and cultured them in conditions similar to those used for expansion of normal colon stem cells Sato et al., 2011) . EPHB2-high tumor cells embedded in matrigel expanded as epithelial tumor organoids ( Figure 5A ), which retained high expression levels of colon stem cell marker genes such as LGR5 and ASCL2 (data not shown). Genomic analysis of the tumor organoids revealed that the two TGFBR2 alleles were inactivated by mutations in this patient (data not shown). Indeed, treatment with TGFBR1-specific inhibitor LY2157299 (Bueno et al., 2008) or the addition of active TGF-b did not modify in vitro growth rates, morphology, or organoid forming activity of this CoCSC-derived culture ( Figures 5A-5C ). Primary CoCSCs expressed higher TGFB levels than did CRC cells lines ( Figure 5D ). When injected in immunodeficient mice, they generated tumors with abundant p-SMAD2 + stromal cells ( Figure 5E , left panel), implying that this primary CoCSCs elicited a TGF-b response in the tumor microenvironment. Feeding mice bearing macroscopic tumors from CoCSCs-derived cultures with LY2157299 blocked TGF-b signaling in the tumor stroma as shown by reduced stromal p-SMAD2 positivity ( Figure 5E , right panel) and downregulated levels of stromal TBRS genes ( Figure 5F ). Importantly, treatment with LY2157299 conferred resistance to the formation of subcutaneous tumors by primary CoCSC-derived cells ( Figures 5G  and 5H ). Remarkably, this TGF-b inhibitor regime also reduced formation of liver metastasis by CoCSCs inoculated via the spleen ( Figures 5I and 5J ). Kinetics of metastatic colonization showed that LY2157299 reduced the number of cells that engrafted the liver immediately after inoculation ( Figure 5I , inset), the opposite behavior of that induced by secretion of high TGF-b levels in CRC cell lines. Of note, these experiments were performed in NSG mice, which rules out that LY2157299 blocked metastasis through changes in the function of the immune system. Altogether, the clinical and functional data described so far indicate that a TGF-b program activated in the tumor microenvironment confers CRC cell competence to overcome the initial phase of metastasis.
Metastasis Initiation by TGF-b-Stimulated Stromal Cells Depends on GP130/STAT3 Signaling in Tumor Epithelial Cells
We next sought to understand the mechanisms behind the potent effect of stromal TGF-b program on the capacity of CRC cells to initiate metastasis. We discovered that subcutaneous tumors and metastases generated in the context of a TGF-b activated microenvironment displayed prominent accumulation of p-STAT3 in CRC cells compared with those derived from control cells ( Figure 6A ; Figures S5A-S5H ). STAT3 signaling depended on GP130 as shown by strong reduction of epithelial p-STAT3 levels upon GP130 shRNA-mediated knockdown in CRC cells ( Figure 6A ; Figures (K) Relative expression levels of some stromal TBRS genes in dissected metastatic nodules. Values are mean ± SEM (n = 3). See also Figure S4 .
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that GP130/STAT3 signaling in cancer cells participated in the enhancement of tumor initiation mediated by stromal TGF-b signaling ( Figure 6B ), but it was not important for the growth of tumors once established ( Figure 6C ). HT29-M6 shCon or HT29-M6 shGP130 cells grew with identical kinetics in vitro ( Figure S5K ) and, in the absence of a source of TGF-b, formed tumors in immunodeficient mice with equivalent latency and frequency ( Figure S5L ). Importantly, these GP130-knockdown HT29-M6 cells secreting TGF-b displayed decreased liver take rates during the first hours following intrasplenic inoculation ( Figures 6D and 6E ) compared to control cells. After the initial phase, the number of tumor cells detected in the liver progressively decreased and, after two weeks, both HT29-M6
shCon/TGF-b and HT29-M6 shGP130/TGF-b cells reinitiated expansion with similar kinetics ( Figure 6D ). The initial clearance of tumor cells is concurrent with apoptosis, as shown by measurement of in vivo caspase activity few hours after inoculation ( Figure 6F ). In the absence of GP130/STAT3 signaling, apoptosis levels were increased, suggesting that this pathway promotes survival in the context of liver colonization.
Interleukin-11, a TGF-b Target Gene in CAFs, Enhances Metastasis Initiation
Interleukin-11 (IL11), a GP130-binding cytokine, was among the genes highly upregulated by TGF-b in colon fibroblast cultures (F-TBRS, Table S4 ), although microarray measurements of IL11 mRNA levels did not associate with cancer recurrence in the cohort of patients with CRC (Table S4 ). HT29-M6 CRC cells responded to recombinant IL11 by activating the GP130/ STAT-3 pathway ( Figure 7A) . Genes upregulated by IL11 in this cell line constituted an IL11-response signature (IL11RS ,  Table S4 ). We found that IL11RS expression correlates tightly with both TGFB and FTBRS levels in CRC samples ( Figure 7B ) and predicts disease relapse ( Figures 7C and 7D) . Purification of stromal populations from primary human CRC samples showed that CAFs were the only source of IL11 in tumors ( Figure 7E ). Experimental metastasis generated from TGF-b secreting KM12L4a cells showed a marked upregulation of IL11 ( Figure 7F ). Importantly, IL11 mRNA was reduced to control levels upon LY2157299 treatment of mice bearing CRC stem cell-derived tumors ( Figure 7F ). We tested the contribution of IL11 to metastasis by engineering CRC cells to autonomously produce this cytokine. Upon implantation in the cecum of mice, we observed no significant differences in the size (not shown), degree of invasion ( Figure 7G ), or histological appearance of primary tumors developed by control or study groups (Figures S6A-S6C ). Yet, KM12L4a IL11 cells effectively colonized liver, lungs, distant lymph nodes, and brain, whereas control cells displayed limited metastatic capacity ( Figure 7G , inset table). In the same set of experiments, KM12L4a cells expressing IL6, a cytokine closely related to IL11, displayed a marginal increase in metastatic capacity ( Figures S6D and S6E ). Intrasplenic inoculation of HT29-M6 IL11 tumor cells confirmed that IL11 enhanced the liver metastatic potential of CRC cells (Figures 7H-7K ). The initial kinetics of metastasis upon intrasplenic inoculation demonstrated that IL11-expressing cells were more proficient at colonizing livers than were control cells ( Figures 7I and 7J ), an effect that was evident as early as 24 hr after inoculation ( Figure 7K ). IL11 rescued apoptosis of tumor cells during the first hours of liver colonization ( Figure 7L ). This behavior paralleled that induced by stromal TGF-b through GP130 signaling in CRC cells shown in Figures 6D-6F .
DISCUSSION
Metastasis involves the regeneration of a full-blown tumor from few disseminated cancer cells. This process is intrinsically inefficient, mainly because of the inability of isolated tumor cells to colonize host tissues and reinitiate tumor growth in a different environment (Luzzi et al., 1998; Valastyan and Weinberg, 2011) . The most accepted view is that competences to overcome this initial bottleneck result from Darwinian selection of appropriate genetic alterations in CRC cells. It is not clear, however, how functions required for colonizing a foreign organ could be selected in the primary tumor where the specific constraints imposed by a different tissue environment are not present (Luzzi et al., 1998; Valastyan and Weinberg, 2011) . Additionally, metastatic traits could be acquired after cancer cells have reached the metastatic site, yet this event would necessarily require that tumor cells gain extravasation capacity and survive in the host environment. Our data argue that key functions required to overcome the initial phase of metastasis are provided by the TGF-b-activated microenvironment. Without the activity of this stromal program, fully aggressive CRC cells fail to colonize the host organ. We speculate that those tumor cells capable of initiating metastasis with high efficiency would possess the capacity to raise such TGF-b response in the environment.
During metastatic colonization, tumor cells may instruct the stroma of the host organ by either secreting TGF-b or recruiting TGF-b-producing cells such macrophages, CAFs, or platelets. An alternative hypothesis is that a TGF-b-driven premetastatic niche could be specified by the primary tumor in foreign tissues through secretion of systemic cytokines, including TGF-b itself. Among the benefits that CRCs obtain via crosstalk with the TGF-b-subverted microenvironment is GP130/STAT3 signaling, which suppresses apoptotic stimuli encountered during the colonization of the metastatic site. Fitting these observations, it has been shown that p-STAT3 accumulation in primary CRC samples associates to advanced disease and poor outcome ( 
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Stromal TGF-b Signals in Colon Cancer Metastasis stimulated CAFs, confers robust metastatic capacity to CRC cells. On a side note, IL11 is also a megakaryopoietic cytokine that stimulates platelet production (Musashi et al., 1991; Teramura et al., 1992) , and recombinant IL11 is an efficient supportive therapy in patients with malignancies who develop thrombocytopenia as a side effect of chemotherapeutic treatment (Bhatia et al., 2007) . Therefore, the prometastatic effect of IL11 described here calls for a reassessment of the use of this cytokine in an adjuvant setting. On the other hand, correlations between elevated platelet counts, referred to as thrombocytosis, and poor prognosis have been reported for many solid cancers, including gastrointestinal tumors (Ikeda et al., 2002; Nouso et al., 2008) . Platelets protect circulating tumor cells from immune system, as well as assist them during extravasation (Gay and Felding-Habermann, 2011 ). In addition, platelets are a rich source of TGF-b (Labelle et al., 2011) . It is thus possible that tumor-derived TGF-b may promote IL11 production from stromal cells to increase platelet activation, which may further enhance stromal TGF-b response. Besides IL11, the TGF-b response signatures include some previously described prometastatic factors in other tumor types, such as ANGPTL4 (Padua et al., 2008) , PTHLH (Yin et al., 1999) , HBEGF (Bos et al., 2009) , CTGF (Kang et al., 2003) , TNC (Oskarsson et al., 2011) , and JAG1 (Sethi et al., 2011; Sonoshita et al., 2011) . For instance, ANGPTL4 mRNA levels are induced by TGF-b in fibroblasts (Table S4 ). This secreted factor has been previously shown to mediate intravasation of breast cancer cells into lungs (Padua et al., 2008) . Consistent with this observation, our assays show enhancement of lung metastatic capacity by CRC cells upon activation of stromal TGF-b program. JAG1 participates in breast cancer metastasis to the bone (Sethi et al., 2011) , and activation of Notch signaling in CRC cells by endothelial cell-expressed JAG1 promotes transendothelial migration during liver and lung metastasis (Sonoshita et al., 2011) . Indeed, we found that JAG1 is a TGF-b response gene in endothelial cells (Table S4) . Therefore, besides survival during the colonization phase of metastasis, the program activated by TGF-b in the microenvironment likely influences additional functions required to complete the metastasic process. Importantly, in contrast to CRC, the expression of ANGPTL4, PTHLH, CTGF, or JAG1 is induced autonomously in breast cancer cells activated by TGF-b (Kang et al., 2003; Padua et al., 2008; Yin et al., 1999) . IL11 itself is a TGF-b target gene in breast cancer cells, with an important role during bone metastasis formation (Kang et al., 2005; Kang et al., 2003) . It thus appears that, in the context of a lack of response to TGF-b, CRC cells instead achieve similar abilities by engaging the microenvironment in a TGF-b-dependent manner. It would be interesting to analyze whether this may be a general response in other cancer types that bear inactivating mutations in TGF-b pathway components, such as pancreatic cancer.
The invasive adenocarcinomas developed in mouse models bearing compound mutations in Smad4 and Apc course with a prominent accumulation of reactive stroma (Kitamura et al., 2009; Takaku et al., 1998) . Although it is not clear whether this effect depends on increased levels of TGF-b signaling in the microenvironment, Tgfbr2 deletion in an Apc mutant background raises production of TGFB1 in tumors (Muñ oz et al., 2006) . It is thus plausible that CRCs evolve toward a favorable scenario for metastasis by combining an increase of TGF-b signaling in stromal cells with the acquisition of inactivating mutations in TGF-b pathway components in the cancer cells. The majority of CRCs display moderate-to-high TGF-b expression levels, which may help explain the high rates of CRC metastasis. Importantly, we discovered a subgroup of tumors (10%-20% of all CRCs) displaying invasion and/or local dissemination (i.e., AJCC stage II and III) yet with low TGF-b production that did not relapse after surgical intervention. Therefore, besides AJCC staging, our findings call for the assessment of TGF-b pathway activation in stromal cells as a central criterion for patient stratification. Several targeted therapies against TGF-b signaling, including LY2157299, are currently being evaluated for treatment of different cancer types (Tan et al., 2009; Yingling et al., 2004) . Although their efficacy is not yet known, our observations predict that pharmacological inhibition of TGF-b signaling may prevent CRC relapse and metastasis when treating patients at early time point of the process.
EXPERIMENTAL PROCEDURES Profile Data Sets
We defined overall TGF-b levels (TGFB) as the average expression of TGFB1, TGFB2, and TGFB3 mRNAs in a given sample (see Supplemental Information). Data sets corresponding to human colon adenomas and carcinomas have been previously described (Sabates-Bellver et al., 2007; Van der Flier et al., 2007) . To correlate TGFB and TBRS expression with clinical disease progression, we pooled two publicly available sets of Affymetrix transcriptomic profiles (GSE17537 and GSE14333) corresponding to primary CRCs for which clinical follow-up was available. GSE17537 (Smith et al., 2010) is composed of 55 patients with colon cancer treated at Vanderbilt University Medical Center (Nashville, TN, USA). GSE14333 (Jorissen et al., 2009 ) contains a pool of 290 patients with CRC treated at two different hospitals: Peter MacCallum Cancer Center (Australia) and H. Lee Moffitt Cancer Center (USA). The representation of tumor samples at different AJCC stages in these cohorts follows the natural distribution of patients with CRC receiving standard treatment in the aforementioned hospitals. Descriptive statistics (Table S1) as well as univariate analysis of clinical progression parameters (Table S2) in this metacohort are included as Supplemental Information. The TGF-b response signatures used in this study are detailed in Table S4 .
Orthotopic Mouse Studies
All experiments with mouse models were approved by the animal care and use committee of the Barcelona Science Park (CEEA-PCB) and the Catalan Government. Cells were injected subcutaneously in 5-6-week-old Swiss nude or NSG mice (Jackson Laboratories), which were followed for the periods described. Tumor appearance was assessed by palpation. Five-tosix-week-old Balb/c nude or NSG mice (Jackson Laboratories) were used to perform metastasis experiments by intrasplenic injection (Warren et al., 1995) or intracecum injection (Cé spedes et al., 2007) .
Clinical Material
Biological samples were obtained from individuals treated at the Hospital del Mar (Barcelona, Spain) or from Hospital Clinic (Barcelona, Spain) under informed consent and approval of the Bank Tumor Committees of each hospital according to Spanish Ethical regulations. The study followed the guidelines of the Declaration of Helsinki and patient's identity of pathological specimens remained anonymous in the context of this study. Experiments were approved by the ethics committee of IRB/Hospital Clinic (project ERC-208488/CRCprogramme).
ACCESSION NUMBERS
The transcriptomic data sets generated for this study have been deposited in GEO with accession number GSE39397. This SuperSeries contains the subset series GSE39394, GSE39395, and GSE39396 as detailed in Supplemental Experimental Procedures.
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